Blood Cancer Clinical Trials & Research at Providence Medical Group
Chronic lymphocytic leukemia and multiple myeloma, blood cancers, represent
a large group of different malignancies. This group includes cancers of
the bone marrow, blood, and lymphatic system, which includes lymph nodes,
lymphatic vessels, tonsils, thymus, spleen, and digestive tract lymphoid
tissue. Leukemia and myeloma, which start in the bone marrow, and lymphoma,
which starts in the lymphatic system, are the most common types of blood
cancer. What causes these cancers is not known.
Providence Medical Group is currently enrolling patients for the following
blood cancer clinical trials:
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR)
Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)
Treatment agent: Pirtobrutinib (LOXO), venetoclax, Rituxamab
Physician:
Jarrod Holmes, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR)
Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - Full Text View - ClinicalTrials.gov
Sponsor: Loxo Oncology, Inc
Location: Providence Cancer Center Santa Rosa, CA